Company profile

KaliVir Immunotherapeutics

Privately held: no public share price (Privately held oncolytic-virus biotech; Series A closed March 2022, no public listing. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.prnewswire.com/news-releases/kalivir-immunotherapeutics-closes-series-a-financing-301504135.html]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
VET3-TGI
Phase 1
Oncolytic vaccinia virus engineered with immunomodulatory transgenesOther
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.